Elevated C-reactive protein in high-risk asymptomatic individuals is strongly associated with the metabolic syndrome  by Mora, Samia et al.
292A ABSTRACTS - Vascular Disease, Hypertension, and Prevention JACC March 19.2003 
is as yet no data providing the independent and quantitative effect of the syndrome on 
subsequent cardiac outcomes. We applied the five year experience of the West of Scot- 
land Coronary Prevention Study (WOSCOPS) to directly quantify the prognostic impact 
of METS. Methods: The study population comprised 6,447 males enrolled in the 
WOSCOPS trial aged 45-64 years, with LDL-C 156-255 mg/dl. Diabetics and subjects 
with fasting glucose x= 126 mgldl were excluded. We defined the presence of METS as 
any three of the following: Body Mass Index >30 kglm2, HDL-C less than 40 mgidl, trig- 
lycerides > 150 mgldl, fasting glucose >= 110 - 125 mgidl. and systolic blood pressure 
>=I30 mmHg or diastolic >= 85 mmHg or treated for hypeltension. Cardiac events were 
defined as fatal or non-fatal CHD, or revascularization (CABG or PTCA). Cox regression 
was used to estimate the independent contribution of METS to events, with age, LDL-C, 
current smoking, and pravastatin treatment as covariates. Results: The overall preva- 
lence of the metabolic syndrome was 23.8%. Cardiac event rates were 12.6% and 7.3% 
for subjects with and without METS respectively (pc.0001). The hazard ratio describing 
the association of METS with events was 1.8 (95%CI: 1.5-2.1, pc.OOOl), which was com- 
parable to age(per 10 years): 1.8(95%CI:1.5-Z.O,p<.OOOl), and greater than smoking: 1.5 
95%CI:1.3-1.8). and LDL-C: 1.4 (95%CI:l .1-i .6,p<.OOl). Conclusions: This study is the 
first reported quantification of the independent association of METS with CHD in a longi- 
tudinal cohort of males. The prognostic impact of METS is similar lo other traditional risk 
factors such as LDL-C, age. and smoking. Therapies which target METS risk factors in 
combination should confer clinical benefit lo METS patients. 
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845-4 Differential Effects of Statins on Hypercholesterolemic 
Patients With Metabolic Syndrome 
Donald 8. Hunninahake, Christie M. Ballantyne, Darbie L. Maccubbin, Awind K. Shah, 
Barry Gumbiner, Yale B. Mitchel. Heart Disease Prevention Clinic, Minneapolis, MN, 
Merck Research Laboratories, Rahway, NJ 
Background: Hypercholesterolemic (HC) patients with metabolic syndrome (MS) are at 
high risk for coronary heart disease (CHD) due to elevated LDL-C and triglycerides (TG), 
and low HDL-C, all independent predictors of CHD. We compared the lipid-modifying effi- 
cacy of simvastatin (S) and atolvastatin (A) in HC patients with MS. 
Methods: This post-hoc analysis was performed on data from a 36-week, multicenter, 
double-blind dose titration study designed to evaluate the effects of S (40-80 mg) and A 
(20-80 mg) on HDL-C in HC patients (LDL-C >I60 mg/dL). Per NCEP ATPIII, patients 
ware classified as having MS if they met 3 or more of the following criteria: TG 2150 mg/ 
dL; HDL-C ~40 (men) or ~50 (women) mg/dL; type 2 diabetes and/or fasting serum glu- 
cose 21 IO mg/dL; hypertension and/or blood pressure Ll3Ok85 mmHg; and body mass 
index 230 (surrogate for waist circumference). 
Results: Of 808 evaluable patients, 212 (26%) had MS at baseline. with 99 and 113 in 
the S and A groups, respectively. At comparable LDL-C- and non-HDL-C-lowerlng 
doses, both drugs produced large reductions in TG with A producing greater decreases 
in 2 of 3 dose comparisons. In contrast, the increases in HDL-C with S were -1.5 to 3- 
fold those observed with A af every dose (table). After 36 weeks, -50% of the MS 
patients in both treatment groups converted to non-MS status. 
Conclusion: Both simvastatin and atorvastatin effectively modified LDL-C, TG and non- 
HDL-C in HC patients with MS; however, simvastatin provided greater increases in HDL- 
C. 
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Elevated C-Reactive Protein in High-Risk Asymptomatic 
Individuals Is Strongly Associated With the Metabolic 
Syndrome 
Samia Mora, Roger S. Blumenthal, Lisa R. Yanek, Taryn F. Moy, Lewis C. Becker, Diane 
M. Becker, Johns Hopkins Medical Institutions, Baltimore. MD 
Background: Chronic inflammation has been associated with certain components of the 
metabolic syndrome (MS), including increased body mass index and serum lipids, but it 
is unclear if inflammation should be considered part of the syndrome. 
Methods: We investigated whether high-sensitivity C-reactive protein (hs-CRP) is inde- 
pendently associated with the clustering of metabolic abnormalities in 388 apparently 
healthy siblings (SIBS) of individuals with premature coronary heart disease (mean age 
of SIBS 52 * 8 years, 43% male, 60% African-American). MS components were defined 
using ATP Ill guidelines for abdominal obesity. high triglycerides, low HDL cholesterol. 
high blood pressure, and high glucose. 
Results: Mean hs-CRP was 4.4 f 3.5 mg/L. There was a significant difference in mean 
hs-CRP in those with MS (z 3 components) compared to those without MS (5.7 versus 
4.0, p<O.OOOl). There was a graded increase in mean hs-CRP levels with increasing 
number of MS components present, p for trend <O.OOOl (Table). Using multiple linear 
regression, each additional component of MS was associated with a 0.9 * 0.1 mg/L 
increase in mean hs-CRP level (p<O.OOOl), after adjusting for age, sex. race. and smok- 
ing status. 
Conclusion: These findings suggest that chronic inflammation is strongly associated 
with the metabolic syndrome in high-risk individuals who may benefit from funher risk- 
stratification using hs-CRP levels. 
MS Components (No.) 0 1 2 3 4 5 
Mean hs-CRP (mglL) 2.2 3.9 4.9 5.4 6.2 6.1 
N 61 98 120 66 31 12 
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845-6 The Association of the Metabolic Syndrome With 
Myocardial Infarction and Stroke in the National Health 
and Nutrition Examination Survey Ill 
John K. Ninomiva, Gilbert J. L’italien, Michael H. Criqui, Joanna L. Whyte. Anthony 
Gamst, Roland S. Chen, University of California, San Diego, School of Medicine 
Epidemiology, San Diego, CA, Bristol-Myers Squibb, PRI, Princeton, NJ 
Background: The association of the Metabolic Syndrome and its component conditions 
with self-reported history of myocardial infarction (Ml) and stroke was evaluated in a 
large cross-sectional population suway. the NHANES Ill, 1988-1994. Methods: Based on 
NCEP Adult Treatment Panel Ill (NCEP-ATP Ill) criteria. we evaluated 10,357 subjects 
for each of the five component conditions of the Metabolic Syndrome: insulin resistance 
(IR). abdominal obesity based on waist circumference (WC), hypertriglyceridemia. low 
HDL-cholesterol, and hypertension (HTN), and the overall syndrome defined as 3 or 
more of the 5 conditions. Logistic regression was used to estimate the association of the 
svndrome. and each of its 5 component conditions individuallv. with Ml and stroke. Mod- 
els were adjusted for age. sex, race and smoking history. SUDAAN software was used to 
weiaht for the complex samolina frame used in NHANES Ill. Results: The prevalence of 
I  
Ml was 3.7%, stroke 2.0% and the combined outcome (either or both) 5.2%. The Meta- 
bolic Syndrome was significantly related in multivariate analysis to Ml (OR = 2.01, 95% 
Cl = 1.53 - 2.84), stroke (OR = 2.16, 95% Cl = 1.48 - 3.16) and the combined outcome 
(OR = 2.05, 95% Cl = 1.64 - 2.57). The combined outcome association was observed in 
both women (OR = 2.20, 95% Cl = 1.56 - 3.11) and men (OR = 1.98, 95% Cl = 1.34 - 
2.78). Among the component conditions, IR (OR = 1.30, 95% Cl = 1.03 - 1.66), low HDL 
(OR = 1.35,95% Cl = 1.05 1.74), HTN (OR = 1.44,95% Cl = 1 .OO, 2.08) and hypertng- 
lycendemia (OR = 1.68, 95% Cl = 1.20 - 2.30) were significantly related to the combined 
outcome in multIvariate analysis; only obesity, as measured by waist circumference, was 
not independently related to disease (OR. = 1 .I 1, 95% Cl = 0.88 - 1.42). Conclusions: 
These results indicate a strong, consistent relationship of the Metabolic Syndrome, as 
defined in NCEP-ATP Ill, with history of MI and stroke. The individual component condi- 
bow. IR, HTN. low HDL and hypertriglycerldemia were all found to be significantly asso- 
ciated with histoly of Ml and stroke. These results emphasize the impoltance of the 
Metabolic Syndrome in the progression of atherosclerotic disease. 
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847-l Lipocalin-Type Prostaglandin D Synthase as a Sensitive 
Biomarker for Coronary Atherosclerosis 
Yoii Kate, Yoshiyuki Kijima. Yasuhiko Mats”-ura, Takenori Yasuda, Yutaka Eguchi. 
Teruo Inoue, Hiroshi Oda, Kousuke Seiki, Nanae Taniguchi, Kousuke Aritake, Haruko 
Kumanogoh. Naomi Eguchi, Yoshihiro Urade, lshinkai Yao General Hospital, Yao, 
Japan, Osaka Bioscience Institute, Suita, Japan 
Background: Lipoprotein(a). C-reactive protein (CRP), and lipocalin-type prostaglandin D 
synthase (L-PGDS) have been proposed as serum markers for coronary artery disease, 
but no consensus has yet been reached. 
Methods: Serum levels of L-PGDS. lipoprotein(a). and CRP were measured I” samples 
taken from the ascending aorta and great cardiac vein in 38 patients with chest symp- 
toms who were investigated by coronary anglography. lmmunohistochemical localization 
and mRNA expression for L-PGDS were determined in autopsy specimens. 
Results: The aortic and venous levels of L-PGDS and the veno-aortic difference were 
increased in patients with single (meaw57.1, 65.2, and 8.1 pgldl, respectively) and mul- 
tiple (69.1, 82.0, and 13.0 wg/dl, respectively) vessel disease compared wth those in the 
patients with normal coronary angiography or coronary risk factors (48.5, 51.6 and 3.1 
pg/dl, respectively). The aoltic and venous levels in patients with multiple vessel disease 
were significantly (p=O.O009-0.046) higher than those of the other 2 groups. The veno- 
aortic differences were significantly higher in patlen& with multiple vessel disease than in 
those with normal coronary anglography (p=O.Ol). However, neither lipoprotein(a) nor 
